explore -WSS

explore

author：fashion 2025-09-30 00:02:46 - browse：96959

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Drinking water from half of US faucets contains PFAS: Study

WSS

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

The Bio Revolution is changing business and society

Sen. Bill Cassidy on how to lower drug prices

North Korean leader's powerful sister says warplanes repelled US spy plane

Bird flu makes raw milk dangerous to consume, mouse study finds

Drinking water from half of US faucets contains PFAS: Study

hotspot

explore

hotspot

The high cost of giving birth even with insurance

What to know about a major upcoming Wegovy heart health study

Sports medicine is finally prioritizing gender equality

Stroke rates rising, especially in working

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Louisiana bill approved classifying abortion pills as controlled substances

Novavax promises a turnaround & Lilly roils the obesity market

What to know about a major upcoming Wegovy heart health study

Medical leaders decry Supreme Court decision on affirmative action

The world needs the new pandemic treaty

focus

Guardant Health colon cancer test endorsed by FDA advisory panel

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Louisiana bill approved classifying abortion pills as controlled substances

Medical students need to learn the potent medicine of empathy

With fresh data, a dynamic duo powers Eli Lilly to new heights

Why some fertility treatments produce more boy babies

hotspot

hotspot

focus

entertainment